1 completed, 1 terminated. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Terminated 1 |
Follow Pseudobulbar Affect (PBA): new trials by email Literature Review of Pseudobulbar Affect (PBA) trials Research Report on Pseudobulbar Affect (PBA)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) Nuedexta (DM 20 mg/Q 10 mg) - Pseudobulbar Affect (PBA), Stroke | Phase 4 | Completed | Avanir Pharmaceuticals | 367 | 2013-02-01 | 2017-03-15 |
| Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease Nuedexta (20/10) - Alzheimer's Disease, Pseudobulbar Affect (PBA) | Phase 4 | Terminated | St. Joseph's Hospital and Medical Center, Phoenix | 34 | 2012-08-28 | 2019-10-29 |
Alzheimer Disease (1) · Brain Injuries, Traumatic (1) · Dementia (1) · Stroke (1)
Brain Diseases (2) · Central Nervous System Diseases (2) · Mental Disorders (2) · Nervous System Diseases (2) · Neurocognitive Disorders (2) · Brain Injuries (1) · Cardiovascular Diseases (1) · Cerebrovascular Disorders (1) · Craniocerebral Trauma (1) · Dementia (1) · Neurodegenerative Diseases (1) · Tauopathies (1) · Trauma, Nervous System (1) · Vascular Diseases (1) · Wounds and Injuries (1)
dextromethorphan - quinidine combination (2)
Avanir Pharmaceuticals (1) · St. Joseph's Hospital and Medical Center, Phoenix (1)
United States (2)